Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 870 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Woman Who Lost Husband to Male Breast Cancer Goes on Road... September 16, 2021 Blood test could tailor treatment after surgery July 14, 2021 Workout Wednesday – Back Stretches Part 2 July 29, 2020 Development of T-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy July 22, 2024 Load more HOT NEWS A Safer, Better Treatment Option for Some Younger Women with Breast... Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer Pembrolizumab Combinations Show Promise in mCRPC Woman Suffers Seizure And Dies After Making Fatal Error With Her...
